沙利度胺治疗儿童炎症性肠病的内镜与组织学愈合
该研究汇总2项多中心试验共70例难治性克罗恩病或溃疡性结肠炎患儿(2-18岁)接受沙利度胺或安慰剂的数据。第8周临床缓解42例(60.0%)、临床应答45例(64.2%);第52周38例(54.3%)仍处于临床缓解或应答,29例(41.4%)达黏膜愈合,20例(27.7%)达组织学愈合。作者结论为52周沙利度胺治疗使54.3%患儿获临床缓解,其中75.3%伴黏膜愈合、52.6%伴组织学愈合,尚需进一步研究确定其对疾病长期进展的影响。
要点
- 第52周54.3%患儿仍临床缓解或应答,41.4%达黏膜愈合,27.7%达组织学愈合。
- 达临床缓解或应答者中75.3%伴黏膜愈合、52.6%伴组织学愈合。
- 红细胞沉降率升高与黏膜愈合概率降低相关(校正OR 0.96,95%CI 0.93-0.98,P=0.006)。
核心结论
- 在2项儿童克罗恩病或溃疡性结肠炎临床试验的长期分析中,52周沙利度胺治疗使54.3%的回结肠或结肠病变患儿获临床缓解。
- 这些患者中75.3%伴黏膜愈合、52.6%伴组织学愈合。
- 尚需进一步研究确定沙利度胺治疗如何影响炎症性肠病的长期进展。
研究设计与样本
- 汇总2项多中心试验(NCT00720538)数据,共70例2-18岁难治性克罗恩病或溃疡性结肠炎患儿(回结肠或结肠病变),接受沙利度胺或安慰剂。
- 第8周有临床应答者于研究第12周和第52周接受内镜检查并取活检。
- 溃疡性结肠炎炎症严重度用Mayo评分评估,克罗恩病用4级系统评估;活检评估活动性炎症、糜烂或溃疡及隐窝脓肿并给予组织学评分。
主要发现
- 第8周临床缓解42例(60.0%),临床应答45例(64.2%)。
- 第52周共38例(54.3%)仍处于临床缓解或仍有临床应答;29例(41.4%)达黏膜愈合(糜烂或溃疡完全愈合),20例(27.7%)达组织学愈合(炎症标志物完全消失)。
- 达临床缓解或临床应答的患者中,75.3%同时有黏膜愈合,52.6%同时有组织学愈合。
- 红细胞沉降率值升高时黏膜愈合概率显著下降(校正比值比0.96,95%CI 0.93-0.98,P=0.006)。
关键数值与推荐
- 克罗恩病临床缓解定义为儿童克罗恩病活动指数评分≤10分,临床应答定义为较基线下降至少50%。
- 溃疡性结肠炎临床缓解定义为儿童溃疡性结肠炎活动指数评分低于10分,临床应答定义为较基线下降至少20分。
- 黏膜愈合定义为糜烂或溃疡完全愈合;组织学愈合定义为炎症标志物完全消失。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出尚需进一步研究确定沙利度胺治疗如何影响炎症性肠病的长期进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Mucosal healing, determined by endoscopic evaluation, is one of the most important prognostic markers for patients with inflammatory bowel diseases. Findings from histologic evaluation, however, could complement findings from endoscopy in assessing mucosal responses to treatment. We analyzed long-term results of children treated with thalidomide to determine the association between clinical response and histology and endoscopy findings. METHODS: We collected data from 2 multicenter trials of 70 children with refractory Crohn's disease (CD) or ulcerative colitis (UC) (2-18 years old; ileocolonic or colonic disease) given thalidomide or placebo (NCT00720538). Clinical remission and clinical response at 8 weeks were defined as a pediatric CD activity index scores 10 points or lower and a decrease of at least 50% from baseline, respectively, for patients with CD; and as a pediatric UC activity index score below 10 and a decrease of at least 20 points from baseline, respectively, for patients with UC. Patients with a clinical response to 8 weeks' treatment with thalidomide underwent endoscopic examination with biopsy collection at study weeks 12 and 52. Severity of inflammation in patients with UC was assessed by Mayo score and in patients with CD by 4-grade system. Biopsies were assessed for signs of active inflammation, erosion or ulceration, and crypt abscesses and assigned a histologic score. RESULTS: Clinical remission was observed in 42 patients (60.0%) and clinical response in 45 patients (64.2%) at Week 8. At Week 52, a total of 38 patients (54.3%) were still in clinical remission or still had a clinical response; 29 patients (41.4%) had mucosal healing, defined as complete healing of erosions or ulcerations, and 20 patients (27.7%) had histologic healing, defined as complete absence of markers of inflammation. Of patients with clinical remission or clinical response, 75.3% also had mucosal healing and 52.6% also had histologic healing. The probability of achieving mucosal healing decreased significantly with increasing values of erythrocyte sedimentation rate (adjusted odds ratio, 0.96; 95% CI, 0.93-0.98; P = .006). CONCLUSIONS: In a long-term analysis of data from 2 clinical trials of pediatric patients with CD or UC, 52 weeks' treatment with thalidomide led to clinical remission in 54.3% of patients with ileocolonic or colonic disease; of these patients, 75.3% had mucosal healing and 52.6% also had histologic healing. Further studies are needed to determine how thalidomide therapy affects long-term progression of inflammatory bowel diseases. (ClinicalTrials.gov number NCT00720538).
引用
- Lazzerini M, Villanacci V, Pellegrin MC, et al. Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide. Clin Gastroenterol Hepatol. 2017. PMID: 28286192. doi:10.1016/j.cgh.2017.02.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。